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ABSTRACT
Objective To determine whether BCG revaccination at
19 months of age reduces overall child mortality.
Design Randomised trial, with follow-up to age 5.
Setting A health project in Bissau, Guinea-Bissau, which
maintains a health and demographic surveillance system
in an urban area with 90000 inhabitants.
Participants 2871 children aged 19 months to 5 years
with low or no reactivity to tuberculin and who were not
severely sick on the day of enrolment.
Intervention BCG vaccination or no vaccination (control).
Main outcome measure Hazard ratios for mortality.
Results77childrendiedduringfollow-up.Comparedwith
controls,theBCGrevaccinatedchildrenhadahazardratio
of 1.20 (95% confidence interval 0.77 to 1.89). Two
hundred and fifty children were admitted to hospital for
thefirsttimebetweenenrolmentandtheendofthestudy,
with an incidence rate ratio for BCG revaccinated children
versus controls of 1.04 (0.81 to 1.33). The trial was
stoppedprematurelybecauseofaclusterofdeathsinthe
BCG arm of the study. This increase in mortality occurred
at a time when many children had received missing
vaccinations or vitamin A or iron supplementation; the
hazardratioforBCGrevaccinatedchildrencomparedwith
controls was 2.69 (1.05 to 6.88) in the period after these
campaigns. Throughout the trial, the effect of BCG
revaccination on mortality was significantly different
(P=0.006) in children who had received diphtheria-
tetanus-pertussis (DTP) booster vaccination before
enrolment (hazard ratio 0.36, 0.13 to 0.99) and children
whohadnotreceivedtheboosterbeforeenrolment(1.78,
1.04 to 3.04).
Conclusions There was no overall beneficial effect of
being revaccinated with BCG. The effect of BCG
revaccination on mortality might depend on other health
interventions.
Trial registration Clinical Trials ICA4-CT-2002-10053-
REVAC.
INTRODUCTION
Routine infant vaccines currently used in low income
countries were not tested in randomised trials for their
impact on overall child survival before their
introduction.
1 It has been assumed that the impact of
a vaccine on mortality is proportional to the vaccine’s
efficacy and the contribution of the target disease to
overallmortality.Thepast15yearsofresearchonvac-
cines in low income countries, however, have shown
that this assumption is not a tenable basis for vaccina-
tion policy
1-4; vaccines might have important non-spe-
cific effects. This is best documented for standard
measlesvaccine.Numerousstudiesofmeaslesvaccine
have reported significant reductions in all cause mor-
tality that could not be explained by the prevention of
acute measles or its long term consequences.
1 Further-
more, girls who received high titre measles vaccines
had twice the mortality compared with girls who had
received standard measles vaccine.
23 As high titre
measles vaccines are fully protective against measles
infection, this suggests that non-specific effects are
importantforthetotalimpactofavaccineonmortality.
BCG vaccination might also have non-specific ben-
eficial effects on overall mortality.
4 When it was intro-
ducedinhighincomecountriesinthe1920sand1930s,
the vaccine was said to have a beneficial effect beyond
protection against tuberculosis.
5 A few of the well
designed studies (randomisation, alternation) compar-
ing individuals who were or were not vaccinated with
BCG looked at the effect on mortality associated with
tuberculosis and all cause mortality. All such studies,
including general population studies
67 and studies
among contacts of people with tuberculosis,
89 found
lower mortality from other causes among those who
received the BCG vaccination. Recently, several
observational studies in low income countries have
reported that BCG was associated with a reduction in
mortality that could not be explained by prevention
against tuberculosis, particularly in girls.
1011 As rando-
misedstudiesofBCGinlowincomecountrieshavenot
beencarriedout,wecannotbecertainabouttheextent
of these effects.
Diphtheria-tetanus-pertussis (DTP) vaccine has
been associated with increased mortality, especially in
girls.
312-15 The excess female mortality after high titre
measles vaccine
3 and standard measles vaccine
12 has
been shown to be associated with receipt of DTP vac-
cine after the measles vaccine. Thus we started two
trials of interventions designed to ameliorate these
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vided BCG revaccination after DTP booster vaccina-
tion at 18 months, with the aim of inducing beneficial
immune stimulation. Secondly, reported elsewhere,
16
we administered measles vaccine early at age 4.
5 months after the third dose of DTP vaccine to see
whether this would reduce mortality before all chil-
dren received their measles vaccination at 9 months.
There are different policies regarding BCG
revaccination throughout the world.
17-22 The World
Health Organization (WHO) does not recommend
BCG revaccination (www.who.int/immunization/
wer7904BCG_Jan04_position_paper.pdf), but several
countriesstillrevaccinateteenagers.Thoughsomestu-
dies have documented that PPD (tuberculin purified
protein derivative or Mantoux test) and scar reactions
get largerwith revaccination,
2324 others have found no
effect of revaccination on protection against pulmon-
ary tuberculosis but found that it might improve pro-
tection against leprosy.
1724 Only one study has
reported overall mortality after revaccination with
BCG. In 1930-50 the Pasteur Institute in Alger con-
ducted a large study with alternate allocation of
41000 children. They found that vaccination at birth
and revaccination with oral BCG at age 1 and 3 years
was associated with a 27% reduction in mortality (95%
confidence interval 22% to 31%) between 1 and
11 years.
2526 The impact on overall mortality of revac-
cination with intradermal BCG vaccination has not
been examined. We assessed whether intradermal
revaccination with BCG is associated with a reduction
inchildhoodmortalitybetween19monthsand5years.
METHODS
Setting, study population, and routine data collection
The study was conducted in the Bandim Health Pro-
ject’s study area, which covers six districts with about
90000 inhabitants or around 30% of the population of
thecapital.Theprojecthasimplementedaroutinedata
collection system in this area. A census has been car-
ried out regularly, and all houses have painted num-
bers and have been mapped. All residents have an
identification number in the census files, and informa-
tion on place of living can be retrieved from these files
along with socioeconomic and demographic informa-
tion.Allhousesarevisitedeverymonthtoregisternew
pregnancies and births. All children are given a
UNICEF road to health card at birth, which is used to
trace children when they attend health centres or the
hospital. All children are visited at home every three
months until the age of 3 years and information col-
lected on risk factors associated with child survival,
including breastfeeding status, infections, admissions
to hospital, vaccination status, and living with the
mother. There are three health centres in the area.
Vaccination status—Data on vaccination status are
gathered in two complementary ways. Firstly, all vac-
cinations given at the three health centres in the study
areaareregisteredonthedayofvaccination.Thiscov-
ers more than 80% of the vaccinations received in the
study area but does not account for those obtained
outside the study areas, such as when the mother is
travelling or if she lives close to another health centre
outside the study area. Secondly, at the regular three
monthly home visits, the field assistant brings a list on
which previously registered vaccinations are already
printed. The vaccination card is inspected and the
field assistant adds newly received vaccinations to the
list. Such data are obtained only from children whose
vaccination card can be seen at the home visit and,
importantly, only from surviving children.
27
Survivalstatus—Observationsondeathsareobtained
from the paediatric ward and through the three
monthlyhomevisits.MothersfromBissauoftentravel
to visit relatives living in other parts of the country.
Most women earn their living in the cashew harvest,
going to the rural areas from April to June, and about
20% of the mothers and their children are travelling at
any given time. It is always possible, however, to
obtain information on the survival status of a child; if
a child dies in the rural areas, the family in the city will
be informed immediately.
Study objective
We hoped to reduce a suspected negative effect of
booster DTP vaccination at 18 months of age
312-1528
byrevaccinatingwithBCGafterDTPboostervaccina-
tion.OurmainobjectivewastoexaminewhetherBCG
revaccination would reduce child mortality by 30%.
Study design
WhenthetrialstartedinJuly2002thevaccinationpro-
gramme in Guinea-Bissau comprised BCG and oral
polio vaccine at birth; DTP and oral polio vaccine at
age 6, 10, and 14 weeks; measles vaccine at 9 months;
and booster doses of DTP and oral polio vaccine at
18 months. To prevent interference with the booster
doses of DTP and oral polio vaccine, BCG revaccina-
tionwasimplementedat19months.Werecruitedchil-
dren thought not to have tuberculosis and followed
them for mortality and admissions to hospital until
the age of 5 years. The analysis controlled for age and
sex. We separately analysed children who were
exposed to tuberculosis because they lived in the
same house as a person with diagnosed tuberculosis.
InMay2006theMinistryofHealthorganisedagen-
eral measles vaccination campaign for all children
under 15, when the mean age of children in the
enrolled cohort was 5.4. We did not know about this
campaign when we planned the BCG study. We have
previouslyshownthatmeaslesvaccinehasstrongnon-
specific effects on child survival.
13 As little follow-up
was left and additional measles vaccination would
make it impossible to measure any difference between
BCG vaccinated children and controls, we decided to
end follow-up in May 2006.
Intervention
Children enrolled in the study were randomised to
receive BCG vaccine (Statens Serum Institut, Copen-
hagen,Denmark)ornovaccine.TheBCGvaccinewas
RESEARCH
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recommended by WHO for this age group. In all
other respects the two groups were treated equally;
they received the same clinical examination and treat-
ment before enrolment, the same home visits to assess
adverse events and tuberculin skin test reactions, and
the same access to consultations and essential drugs.
Outcomes
Our primary outcome was survival between
19 months and 5 years. Secondary outcomes included
admission to hospital, BCG scarring, tuberculin reac-
tivity, and malaria morbidity. As reported elsewhere
wefollowedasubgroupofthestudycohortformalaria
infection.
29 In another subgroup, we collected blood
samples to measure changes in cytokine profile after
BCG revaccination. We report the results for overall
mortality, admission to hospital, and adverse events.
Sample size
Based on data from 1990-8, we expected an annual
mortality of 4.0% between the ages of 18 months and
4 years. With a significance level of 5%, a power of
80%, and 1:1 allocation of children to revaccination
and control groups, we needed 3750 child years in
each group with 150 deaths in the control group to
document a 30% reduction in mortality. Assuming
recruitment of 3000 children over a two year period
with an average follow-up of three years, and no
more than a 20% loss to follow-up, we expected to
have at least 7500 child years of follow-up in the trial.
Enrolment
At18-19monthsofage,allchildrenregisteredasliving
inthestudyareawereassessedforBCGscarandtuber-
culin reaction. Tuberculin reactivity was measured
with the Mantoux method, with an intradermal injec-
tion of 2 tuberculin units (RT23, Statens Serum Insti-
tute) and subsequent reading within 48-72 hours of
bulae formation with the ball point technique. Chil-
dren with a tuberculin reaction of 15 mm or more
were referred to an experienced clinician to be exam-
inedforpossibletuberculosisinfection.Ifthechildwas
considered to need tuberculosis prophylaxis or tuber-
culosistreatmentaccordingtoadiagnosticscoringsys-
tem this was supplied as currently recommended by
the local tuberculosis programme.
30
A field worker contacted the mothers/guardians of
the children during the morning. They explained the
study and filled in a questionnaire on background fac-
tors and vaccination status. They documented major
risk factors for childhood mortality, including expo-
suretotuberculosis,recentinfections,accesstomalaria
drugs, ethnic group, mother’s education, and recent
drug consumption. The mother was asked to bring
the child to the health centre in the afternoon. When
the study started in July 2002 four districts and two
health centres participated. From the end of April
2003, two more districts and the third health centre in
the area were included.
Inclusion criteria were residence in the study area, a
Mantoux test reaction of less than 15 mm, and being
sufficiently healthy to be vaccinated according to the
clinician. Exclusion criteria were a reaction of 15 mm
or more and not being sufficiently healthy to be vacci-
natedaccordingtotheclinician.Childrendidnothave
to have documentation of previous BCG vaccination
or previous booster DTP vaccination to be included.
We assumed that essentially all children had received
BCG during the first year of life, and we were testing
the effect of a general introduction of BCG revaccina-
tion in the community.
Informed consent
In the afternoon, the mothers/guardians of children
presenting at the local health centre received an oral
and a written explanation of the study from a physi-
cian.Thephysicianperformedamedicalexamination.
Clinical examination and treatment was independent
of consent and randomisation group. The clinical
examination included anthropometrics and assess-
ment of vaccination status from the vaccination card.
Children who were missing doses of oral polio, DTP,
ormeaslesvaccineswereadvisedtocompletevaccina-
tions. Children who were ill were not randomised.
They received treatment according to local standards
and were told to return when fully recovered.
Visited at home (n=3048)
Tested for PPD reaction (n=3042)
Screened for eligibility (n=2889)
Randomised (n=2873)
Enrolled:
1st visit (n=2792)
2nd visit (n=81)
Controls (n=1434) Received BCG (n=1437)
Remained in area (n=1048) Remained in area (n=1032)
Died (n=35)
Moved (n=337)
Died (n=42)
Moved (n=338)
Lost to follow-up (n=25)
Refused (n=6)
Lost to follow-up (n=14)
Wrong treatment (n=2)
PPD too big (n=43)
Did not turn up at
  health centre (n=110)
Too sick (n=97)
Returned (n=81)
Fig 1 | BCG revaccination trial profile. PPD=tuberculin purified
protein derivative
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Thedatamanager,whowasnotinvolvedintherecruit-
ment of children, prepared bags of envelopes contain-
ing printed allocation numbers indicating to which of
the two groups the child should be allocated. Alloca-
tion numbers could not be seen by the physician
informing and obtaining consent from the mother/
guardian.
Ifconsentwasobtainedandiftheclinicianconsidered
the child fit for participation, the mother or guardian
was asked to pick an allocation number defining the
randomisation group. This procedure has been used in
several other trialsinthe study area toemphasisetothe
mother that she is participating in a randomised trial.
Randomisation was even between the two groups,
with block randomisation with 40 envelopes per bag.
Masking
There was no placebo for BCG and no “control” vac-
cine was given.
Adverse events
At the beginning of the study, we followed a group of
400revaccinatedand400controlchildrenweeklydur-
ingthefirstmonthafterenrolmenttoexaminemorbid-
ity and to monitor possible adverse effects of the
vaccination. Vaccination site, tuberculin reactivity,
morbidity, and hospital visits were assessed after two
and six months. We classified pustules ≥10 mm in dia-
meter as a large local reaction to BCG injection com-
pared with the normal local reaction to BCG (pustule,
spontaneous drainage, and scarring).
3132
WedidnotexpectthatKoch-likereactionswouldbe
commoninthisagegroup.Wedidplan,however,that
if too many adverse reactions were seen among chil-
dren with a positive tuberculin test result (1-14 mm),
we would include only children with negative results
in the continuation of the trial.
Follow-up
Apart from the three monthly routine surveillance vis-
itstoallchildreninthestudyarea,allchildrenenrolled
in the trial were visited two and six months after inclu-
sion to assess tuberculin reaction and BCG scarring.
The children were followed for admissions to hospital
and mortality to age 5 years through the demographic
and hospital surveillance systems.A trained local phy-
sician implemented a standardised verbal autopsy
when one of the study children had died. We intended
to censor deathsfrom injury in the survival analyses as
theseareunrelatedtoanyimmunestimulatoryeffectof
BCG. None of the participating children reportedly
died from injuries.
Admissions to hospital—Two assistants from the Ban-
dim Health Project work at the national hospital and
register all children admitted to the only paediatric
ward in the country. Using the vaccination cards they
attempt to identify all children from the study area.
Tuberculosis surveillance—The project has maintained
a tuberculosis surveillance system in the study area
since 1997, and it has therefore been possible to con-
duct separate analyses for children who were or were
not exposed to tuberculosis at home.
303334
Campaigns—The project documented individual
participation in all vitamin A supplementation and
vaccination campaigns in the study area during the
conduct of the present trial. The annual campaigns
conducted in 2002,
35 2004, and 2005 provided oral
polio vaccine and vitamin A supplementation. These
campaigns were based on small mobile teams visiting
all houses in the study area. Each team was accompa-
niedbyaprojectfieldworker,whonotedparticipation
onaregistrationlistforallchildreninthesubdistrict.In
2003 there was no oral polio vaccine campaign but a
campaign was organised in November 2003 with vita-
min A supplementation and missing vaccines being
distributed from 15 fixed posts in the area.
36 At each
post, project field workers documented participation.
Table 1 |Distribution of background factors for two trial arms. Figures are numbers
(percentage) unless stated otherwise
Variables
BCG revaccination
group (n=1437)
Control group
(n=1434)
Boys 732 (51) 704 (49)
Twin 49 (3) 56 (4)
Ethnicity (% Pepel) 482 (34) 505 (35)
Living in Bandim-1 (district) 557 (39) 571 (40)
Family
Mother’s mean (SD) No of deliveries 2.8 (1.9) 2.9 (1.9)
Mean No (SD) of children still alive 2.6 (1.6) 2.6 (1.6)
Mother died 3 (0.2) 5 (0.3)
Father died 10 (0.7) 14 (1.0)
Mother had BCG scar 524 (36) 548 (38)
Mother had smallpox scar 84 (6) 89 (6)
Apartment had only 1 room 586 (41) 577 (40)
Median (IQR) No of people per family 6 (4-8) 6 (4-8)
Had chloroquine at home 165 (11) 172 (12)
Tuberculosis patient in house 46 (3) 40 (3)
Had pigs in house 301 (21) 317 (22)
Status at enrolment
Breast feeding (%) 949 (66) 983 (69)
Previous admission to hospital 144 (10) 165 (12)
Documented admission to paediatric ward before enrolment 127 (9) 130 (9)
Median (IQR) arm circumference (mm) 148 (140-154) 148 (140-154)
Median (IQR) height (cm) 81 (78-83) 81 (78-83)
Median (IQR) weight (kg) 10.1 (9.3-11.1) 10.2 (9.4-11.1)
Diarrhoea* 119 (8) 137 (10)
Fever* 443 (31) 442 (31)
Respiratory infection* 265 (18) 260 (18)
Scabies† 93 (6) 59 (4)
Eye infections† 125 (9) 133 (9)
Considered too sick to be enrolled at first visit† 46 (3) 34 (2)
Vaccination status
Showed vaccination card 1298 (90) 1298 (91)
Had BCG scar 1117 (78) 1089 (76)
Measles vaccinated 1301 (91) 1293 (90)
DTP3 1232 (86) 1231 (86)
DTP4 (booster dose) 571 (40) 575 (40)
IQR=interquartile range; DTP=diphtheria-tetanus-pertussis.
*Information reported by mother/guardian.
†Observed by clinician.
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than in the house to house campaigns. In May 2006, a
campaign with measles vaccine administered to all
children aged 6 months to 14 years was conducted in
Guinea-Bissau. This campaign with fixed posts also
included distribution of vitamin A supplementation
to all children aged 6 months to 4 years and mebenda-
zol to children aged 1-4 years. Project field workers at
all fixed posts documented participation. The vaccina-
tion status and survival of all children less than 5 years
was assessed in connection with these campaigns.
Conduct of the trial
As will be apparent from the accompanying commen-
taries and editorial, the present publication is contro-
versial. We had no funding for a data monitoring and
safety board and there were no predefined stopping
rules. The senior author (PA), who is not a clinician
and not involved in clinical care related to any child
in the trial, monitored mortality registered by the rou-
tine registration system quarterly as a check of safety.
As previous experience has shown large and unex-
pected effects of vaccinations on mortality
31537 we
thoughtitessentialtoidentifyunexpected safetyissues
when a potential new vaccination strategy is tested in
this environment with high childhood mortality.
Safety monitoring
WhenwecheckeddatainthebeginningofApril2004,
we identified a sudden increase in mortality starting at
the end of 2003. Eighteen children in the BCG vacci-
nation and four in the control group had died between
November 2003 and March 2004, whereas there had
beennineand14deaths,respectively,inthepreceding
14 months since the start of the trial. We decided to
stop the trial temporarily to prevent a possible but
unknown risk to more children; at that time only 130
of the planned 3000 children had not been enrolled.
TheincreaseinmortalityapparentlystartedinNovem-
ber, when several campaigns with vitamin A supple-
mentation, missing vaccinations, and iron treatment
had been implemented, and at the same time a major
measles epidemic started in the area. In an attempt to
explain the unexpected findings we used mid-Novem-
ber 2003 as the starting point of the analyses. Use of
any month back to June 2003 as cut point between
thetwoperiods,however,producedasignificantinver-
sion in mortality trends.
When we discovered the increase in mortality we
carried out a follow-up assessment of survival of all
children in the study. Free access to clinical care and
essential drugs, which initially had been planned for
the first year after enrolment, was extended for the
full duration of the study. With longer follow-up
there was no difference between the groups. At the
same time we noted that overall mortality in the trial
was considerably lower (2.5% a year) than originally
anticipated(4%ayear);nofurthercorrectivemeasures
were therefore introduced. As we could not explain
these findings and because the addition of another
130 children would matter little to the outcome of the
trial, we decided not to restart enrolment.
Explorative analyses
Because of the unexpected cluster of deaths, we
initiated a series of explorative analyses to clarify pos-
sible environmental causes. The timing of the trial
coincidedwithmajorhealthinterventions,campaigns,
and epidemics (see legend to fig 1). The explorative
analyses were limited by the routine data available
about these events; the detection of epidemics other
than measles was restricted by the limited diagnostic
data collected at the paediatric ward. The paediatric
ward was totally overbooked by measles cases in pre-
cisely the months of the cluster.
It should be noted that the statistical analysis of the
cluster was conducted with a method that does not
dependonsettingspecificdatesfordefiningthecluster
(see below). The explorative analysis of possible
causes, however, had to be restricted to the period in
which the potential cause was operational. When the
cluster was detected it looked like something had
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Fig 2 | Number of deaths by month, July 2002 to May 2006 (numbers should be interpreted
with caution as number of enrolled children and their average age changed over time).
Sequence of events: recruitment to trial started in July 2002; oral polio vaccine and vitamin A
supplementation campaign (high coverage) occurred in October and November 2002; malaria
survey and iron supplementation in August and November 2003; measles epidemic in
November 2003-May 2004; missed vaccines and vitamin A supplementation campaign (low
coverage) in November 2003; recruitment stopped in April 2004; oral polio vaccine and
vitamin A supplementation campaign (high coverage) took place in October and November
2004, and October and November 2005; measles vaccine for all aged <15 and vitamin A
supplementation campaign (high coverage) and end of follow-up was in May 2006
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tation and missing vaccinations campaign had
occurredinthethirdweekofNovember,
36themeasles
epidemic had gained strength around this time, and
ironsupplementshadbeendistributedinmid-Novem-
ber. We therefore focused our explorative analyses of
increased mortality on the period mid-November
2003toMarch2004.Hence,July2002tomid-Novem-
ber 2003 was the period before the increase and April
2004 to May 2006 the period after the increase.
WeplannedtomeasuretheeffectofBCGrevaccina-
tion at age 19 months, after DTP vaccination, which
was usually administered at 18 months. After the pro-
tocol was originally written, we found that the
sequence of vaccinations—for example, DTP vaccine
givenaftermeaslesvaccine—hasamajorimpactonthe
mortality effect of a trial.
3121638We therefore also con-
ductedexplorativeanalysesofthesequenceofvaccina-
tion and the effect of other vaccines administered after
enrolment in the trial.
Statistical analyses
As defined by the protocol, we compared admissions
to hospital and mortality rates in Cox proportional
hazards analyses, controlling for age as underlying
time and sex, to estimate incidence rate ratios for
admission to hospital and hazard ratios for mortality
for the two arms of the study. Results were presented
as hazard ratios with 95% confidence intervals. The
assumption of proportionality was tested in several
models with age, time since enrolment, and calendar
time as underlying scale. The Kaplan-Meier method
was used to depict crude cumulative mortality curves.
Children were followed to death, migration, age
5 years, or the general measles vaccination campaign
in May 2006,whichever came first. Theanalysisof the
increase in mortality was censored 1 April 2004—that
is, at the time we noted an unusual distribution of
deaths. We used the non-parametric total-time-on-test
plot and total-time-on-test statistics for censored data
39
to test the hypothesis of an increase in mortality. The
total-time-on-test determines whether the mortality
intensity is constant versus the alternative (increasing
or decreasing). The test does not need to split the fol-
low-up into separate periods and thus avoids the pro-
blem of defining cut points for testing an increased or
decreased mortality rate. For the test plot, boundaries
corresponding to a Kolmogorov-Smirnov-type test
canbedrawnandifthetotal-time-on-testcurvecrosses
anyoftheboundariesthehypothesisofaconstantmor-
tality rate can be rejected.
39 For the total-time-on-test
we used calendar time as the time scale with time unit
equal to days and interpreted a significant result as an
increase or decrease of mortality during the study per-
iod.Aseparatetestwascalculatedforeachrandomisa-
tion group.
RESULTS
Trial children
Between July 2002 and April 2004 we enrolled 2873
(96%) of the planned 3000 children (fig 1). Two chil-
dren received the opposite treatment to the one indi-
cated by their randomisation number and were not
considered further. Thirty nine children (1%) had no
follow-up beyond the day of enrolment, leaving 2832
children for analysis. Until censoring, enrolled chil-
dren contributed 6827 of the planned 7500 person
years of follow-up. There were no major differences
in socioeconomic and biological background factors
for the children enrolled in the two arms of the trial,
except that revaccinated children had more scabies
than control children (6% v 4%) (table 1).
Main outcome: overall mortality
Figure2showsthedistributionofdeathsovertime,and
figure 3 shows cumulative mortality curves. BCG
revaccination had no overall effect on mortality, the
hazard ratio for BCG revaccinated children compared
with non-BCG revaccinated children being 1.20 (95%
confidence interval 0.77 to 1.89) (table 2). The pattern
was the same for boys and girls (data not shown). A
totalof98%(2811/2871)ofthechildrenhadvaliddoc-
umentation of primary BCG vaccination. We had no
such documentation for 60 children but 54 claimed to
havereceivedit.Exclusionofthese60childrenhadno
effect on the overall results.
Exclusion of children who had been exposed to
tuberculosis from six months before treatment was
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Fig 3 | Cumulative mortality curves for BCG revaccinated
children and controls
Table 2 |Mortality rates and hazard ratios for BCG revaccinated and controls overall* and by
mortality periods and vaccination status at enrolment
Mortality periods
Mortality rate/100person years (deaths/days) Hazard ratio (95% CI)
for BCG v no BCG BCG revaccination Controls
Total period 1.2 (42/1 242 701) 1.0 (35/1 251 051) 1.20 (0.77 to 1.89)
Explorative analysis: mortality periods
Before increase 1.5 (11/272 281) 2.0 (15/269 691) 0.73 (0.34 to 1.59)
During increase 3.8 (16/154 401) 1.4 (6/155 684) 2.69 (1.05 to 6.88)
After increase 0.7 (15/816 019) 0.6 (14/825 676) 1.08 (0.52 to 2.24)
Explorative analysis: vaccination status at enrolment
Booster DTP before enrolment 0.4 (5/508 443) 1.0 (14/513 158) 0.36 (0.13 to 0.99)
NoboosterDTPbeforeenrolment 1.8 (37/734 258) 1.0 (21/737 893) 1.78 (1.04 to 3.04)
DTP=diphtheria-tetanus-pertussis.
*Includes 2832 children who had at least some follow-up.
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being 1.26 (0.80 to 1.99). Among children exposed to
tuberculosis in their home some time during their life
there were too few deaths to assess whether revaccina-
tion had any significant impact on survival; there was
one death among revaccinated children (1/172961
person days) and five in the control group (5/174755
persondays),thehazardratiobeing0.20(0.02to1.69).
Secondary outcome: adverse events
Amongthefirst400revaccinatedand400controlchil-
dren included, nine (six and three, respectively) had a
positive tuberculin reaction at inclusion (Mantoux test
resultdiameter1-14mm).Duringthetwomonthsafter
inclusion adverse events were assessed in 787 of the
800 children. In the revaccinated children, 5.3% (21/
394) had a large local reaction (≥10 mm). No reactions
persistedsixmonthsaftervaccinationorledtosurgical
drainage, admission to hospital, or death. Among
revaccinated children with a positive tuberculin reac-
tion there was an over-representation of large local
reactions (3/6) compared with revaccinated children
with no tuberculin reaction (18/388) (risk ratio 10.78,
4.30 to 27.01), but two months after revaccination all
had healed vaccination scars with no axillary lymph
node enlargement, fever, suppurative lymphadenitis,
or admission to hospital. As there were no serious or
persistent adverse events among children with a posi-
tive tuberculin reaction, we decided to continue to
include children with a tuberculin reaction <15 mm.
There was a tendency for axillary lymph nodes to be
enlarged(≥15mmindiameter)inthetwomonthsafter
revaccination (24/394), compared with those who
were not revaccinated (14/393) (1.28, 0.99 to 1.65),
that was not present six months after revaccination.
Secondary outcome: admissions to hospital
Between enrolment and the end of the study in 2006,
250 children were admitted to hospital for the first
time, the incidence rate ratio for BCG revaccination
versus control group being 1.04 (0.81 to 1.33). There
was an increase in the incidence of admissions to hos-
pitalat the sametime asmortality increased(see figure
on bmj.com). The annual incidence rate for the whole
study period among the children who were revacci-
nated was 3.1% for girls and 4.8% for boys, giving an
incidence ratio of 0.65 (0.46 to 0.93). Among the
controlgrouptheincidencewas3.8%and3.8%,giving
an incidence rate ratio of 1.00 (0.70 to 1.43) (P=0.094
for interaction between revaccination and sex). Inclu-
sion of subsequent admissions made no difference to
the estimates (data not shown)
Explorative analyses of mortality
Increase in mortality
On 21 April 2004 the research team temporarily
stopped enrolment as the data showed a sudden
increase in mortality in the BCG revaccination arm
(fig 2). During the autumn of 2003, the mortality rate
in the revaccination group increased significantly with
thetotal-time-on-test(P=0.030).Thesameincreasewas
not observed in the control group (P=0.184) (fig 4).
The subsequent follow-up and increased clinical
attention to study childrenafter the increase in mortal-
ity had been detected could have affected the overall
mortality results. If we censured follow-up on 1 April
2004, however, the hazard ratio of BCG revaccinated
children compared with control children was 1.28
(0.72 to 2.26).
Mortality periods
Intheperiodbeforetheincreasedmortality,thehazard
ratiohadbeenslightlybutnotsignificantlylowerinthe
BCG revaccinated group compared with the control
group(table 2).Duringtheperiodofincreasedmortal-
ity, mortality was higher in the BCG revaccination
group, the hazard ratio being 2.69 (1.05 to 6.88). The
hazardratioforBCGrevaccinatedcomparedwithcon-
trol children changed significantly between the period
before the increase and the mid-November 2003 to
March 2004 period (P=0.036, test of interaction).
After the increase there was no difference in mortality,
the hazard ratio being 1.08 (0.52 to 2.24).
Causes of death
The increase in mortality occurred at the beginning of
the dry season. During the period of increased mortal-
ity, deaths were caused by measles, diarrhoea, and
respiratoryinfectionsand only onedeath wasascribed
to malaria (table 3). The causes of deaths might have
differed between the two groups (P=0.088, Fisher’s
exact test). The incidence of measles was equally dis-
tributed between the two groups, while children who
were revaccinated seemed more susceptible to diar-
rhoea and respiratory infections. In the periods with
no increase in mortality, there were no differences in
the causes of death between the children.
There was no interaction between BCG revaccina-
tionandmeaslesinfection.Themeaslesincidenceratio
was not significantly higher (1.18, 0.88 to 1.58) in the
BCG group than in the control group. There was no
difference in case fatality between the groups. Missing
vaccinations and vitamin A supplementation were
linked to excess mortality.
Vitamin A supplementation
The hazard ratio for BCG vaccinated children versus
controlswasfour times higheramongthe twothirds of
Table 3 |Causes of death by randomisation group, period, and vaccination status at
enrolment
Cause of death in verbal
autopsy
Cluster period Non-cluster periods Total
BCG+ No BCG BCG+ No BCG BCG+ No BCG
Malaria 0 1 8 6 9 7
Diarrhoea 6 0 5 7 11 7
Measles 6 4 1 2 7 6
Respiratory infections 3 0 1 0 4 0
Other infections 0 0 3 7 3 7
No information/not done 1 1 7 7 8 8
Total 16 6 26 29 42 35
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tation,whereastherewasnodifferenceamongthechil-
dren who did not receive vitamin A in the campaign
(table 4). Too few children had received iron to mea-
sure a separate effect, but supplementation with vita-
minAorironwasassociatedwithahazardratioof4.97
(1.44 to 17.2) for BCG vaccinated children compared
with controls, whereas it was 0.34 (0.04 to 3.29) for
children who had received neither (P=0.042, test of
homogeneity).
Vaccination status at enrolment
Contrary to our original assumption, only 40% of the
children had received a booster DTP vaccine before
enrolment in the trial (table 1). The BCG vaccinated
children who had received a booster DTP vaccine
beforeenrolment(table 2)hadsignificantlylowermor-
talitythancontrols,thehazardratiobeing0.36(0.13to
0.99). Children missing vaccinations at enrolment
weretoldbythenursestocomebacktothehealthcen-
tre for vaccination and many didso. Thechildren who
had not received a booster DTP vaccine before BCG
vaccination had significantly higher mortality than
controls, the hazard ratio being 1.78 (1.04 to 3.04).
Hence, the effectof BCG revaccinationdifferedsignif-
icantly depending on whether they had received a
booster dose of DTP vaccine or not (P=0.006, test of
homogeneity). The negative effect of BCG revaccina-
tion in those who had not received a booster DTP vac-
cine before enrolment was marked during the period
with increased mortality; the hazard ratio for BCG
revaccination compared with controls was 3.06 (0.99
to 9.51) between mid-November 2003 and March
2004
DISCUSSION
In this randomised trial in Africa, general BCG revac-
cinationat19monthsofagehadnobeneficialeffecton
mortality.Duringashortperiodintheautumnof2003,
however, we observed an increase in mortality in chil-
dren who were revaccinated, which significantly
reversed the hazard ratio for revaccinated and control
children. The unexplained increase in mortality led to
the trial being stopped prematurely to prevent unne-
cessary risk for more children.
In subsequent explorative analyses, the increase in
mortality seemed to be linked to a campaign with vita-
min A supplementation and additionalvaccinationsin
November2003
36andwithirontreatmentinamalaria
survey conducted at the same time.
29 Contrary to our
expectations, BCG revaccination was associated with
highermortalityinchildrenwhohadnotreceivedDTP
booster vaccine before enrolment and were likely to
receive it after revaccination with BCG. This effect
was particularly strong during the period when there
was an increase in mortality. Taken together, these
observations suggest that BCG revaccination—possi-
bly in combination with subsequent immunostimula-
tion with other vaccines and vitamin A—might affect
the immune system, leading to increased mortality.
Strengths and weaknesses
Randomisation worked well, and there were appar-
ently no major differences in baseline characteristics
between the two randomisation groups.
Asseenintheaccompanyingcommentariesandedi-
torial, our publication is controversial for at least two
reasons.Firstly,wedidnotfollowbestpracticerulesfor
conducting randomised controlled trials, which
include having a stopping rule and an external data
monitoring and safety board. Secondly, we stopped
the trial because of the excess mortality detected in
April 2004, which could have been an accidental find-
ing from a statistical perspective. Unfortunately, we
did not have sufficient funding for a data monitoring
andsafetyboard.Thusweproceededwiththetrialand
didourownquarterlysafetymonitoringasthiswasnot
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Fig 4 | Mortality according to total-time-on-test analysis.
Boundaries (dashed lines) corresponding to total-time-on-test
(see text). Under assumption of constant mortality intensity,
plot should approximate straight line with unit slope. If curve
crosses any of boundaries hypothesis of constant mortality
intensity can be rejected
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concern when the mortality ratio between the two
arms of the study changed completely within a short
period. Thus we decided to stop enrolment tempora-
rily to complete the data with follow-up of all children
in the trial—as there is always a delay in the mortality
data available in a surveillance system—and to exam-
ine possible causes of this change. A data monitoring
andsafetyboardwouldprobablynothavestoppedthe
trial because the P value for change was not below
0.001, but, as a result of past experience of unfavour-
able events in such trials and studies of routine
vaccinations,
312-153738 we thought it would be better to
secure safety.
The initial assessment suggested that something had
happened in November 2003 when there were several
campaignsinthecommunity.Itshouldbenoted,how-
ever,that the increasein mortalityin the BCGarmdid
not depend on whether we used a particular definition
oftheperiodbeforeandduringtheincrease.Thetotal-
time-on-test measured a change in mortality over the
wholeperiodofthetrialuntilthedecisionwasmadeto
stop. Hence, an unexpected cluster of deaths was con-
firmed, and we had to conduct explorative analyses to
find possible causes.
Mortality during the trial was considerably lower
than originally anticipated (table 2). There might
have been an improvement in child survival in recent
years because of campaigns and better malaria
control,
40 but better access to clinical examinations
and treatment because of the trial might also have
been a factor. Though the study did not have the
power originally planned, it was large enough to
show a strong differential effect on overall mortality
of BCG revaccination in different periods of the
study and according to vaccination status.
Consistency with previous studies: potential non-specific
effects of BCG revaccination
Possible beneficial effects
From animal studies and cancer treatment we know
that BCG is an immunomodulator, and observational
studies of primary BCG vaccination have suggested
majornon-specificbeneficialeffectsonsurvivalofchil-
dren in low income countries.
441 Only one previous
study has assessed the impact of revaccination on
child survival. In a major study in Algeria using alter-
nate allocation to vaccination and no vaccination with
oral BCG, mortality in the intervention group was
reduced by 27% after BCG revaccination at age 1 and
3 years.
2526 We therefore tested whether BCG revacci-
nation reduced child mortality by 30%.
As expected BCG revaccination was beneficial
amongchildrenwhohadreceivedboosterDTPbefore
enrolment and hence did not receive DTP after enrol-
ment.Whateverbeneficialeffectsexistmightbestron-
ger for girls as girls revaccinated with BCG had
significantly lower rates of admission to hospital than
boysrevaccinatedwithBCG,inconcordancewithpre-
vious findings.
4
Possible negative effects
Our findings show that under certain circumstances
BCGrevaccinationmightbeproblematic.BCGrevac-
cination was associated with an increase in mortality
during the autumn of 2003, which might have started
in November when vitamin A and missing vaccines
wereadministeredinacampaign.
36Furthermore,mor-
talitywasincreasedthroughoutthestudyforBCGvac-
cinated children who had not received booster DTP
before enrolment. These children were likely to
receive booster DTP during follow-up (data not
shown). Hence, BCG revaccination followed by boos-
ter DTP or vitaminA supplementation, or both,might
have contributed to an inadequate response to infec-
tions as the excess deaths in the BCG group in the per-
iod with increased mortality were caused mainly by
diarrhoea and respiratory infections (table 3). We
have previously reported from this campaign that
younger children who received DTP and vitamin A
supplementation simultaneously had increased mor-
tality compared with children who received only vita-
minAsupplementation.
36Studieshavealsofoundthat
children receiving additional doses of DTP after
measles vaccine have increased mortality.
1238
Our study produced several unexpected results. In
an observational study these could have been attribu-
ted to uncontrolled confounding, the selection of sub-
groups, and time periods. We did not randomise
children to receive a booster dose of DTP vaccine
before enrolment in the trial nor did we randomise
the children to vitamin A supplementation in the cam-
paign in 2003. Receipt, or not, of these, however, was
equally distributed between the BCG revaccination
and control groups. As these interactions were found
within a randomised study it seems likely that BCG
revaccination contributes to non-specific negative
immunological effects in some contexts.
There has been concern that BCG might have nega-
tive health consequences in children with HIV.
31 This
is unlikely to have been an explanation in our study
because then the effect should also have been visible
among the BCG revaccinated children before the
increaseinmortalityandamongtheBCGrevaccinated
children who had received booster DTP vaccination
before enrolment. Furthermore, the level of HIV-1
infection is low in the study area, and few children
would have been infected and survived to inclusion at
19 months of age.
42
Table 4 |Mortality rate and hazard ratio for children revaccinated with BCG and controls
during period with increased mortality according to receipt of vitamin A in November 2003
Campaign status in
November 2003
Mortality rate/100 person years (deaths/days) Hazard ratio
(BCG v no BCG) BCG revaccination Controls
Vitamin A supplementation 4.4 (12/99 772) 1.1 (3/102 383) 4.14 (1.17 to 14.7)
No vitamin A 2.7 (4/54 629) 2.1 (3/53 301) 1.29 (0.29 to 5.75)
Total 3.8 (16/154 401) 1.4 (6/155 684) 2.69 (1.05 to 6.88)
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Therearegenerallessonsfromthepresentrandomised
trial.Firstly, non-specific effectsof vaccinesare impor-
tant for child survival in low income countries. As the
non-specific effects happened within a randomised
trial, it seems unlikely that uncontrolled confounding
or selection bias can explain the observed contrasting
trends.
Secondly, BCG revaccination might have had a
negativeeffectwhengivenwithvitaminAsupplemen-
tation and when booster DTP was given after BCG
revaccination. We have recently reported from
another randomised trial that vitamin A supplementa-
tion at birth
43 interacted negatively with DTP, particu-
larly for girls.
4445 A negative interaction between DTP
vaccine and vitamin A supplementation was also
observedinarandomisedtrialinGhana.
38Thepresent
trialsupportsthe theorythatadministrationofvitamin
A might amplify the non-specific effects of vaccines, a
hypothesis we proposed several years ago.
46 The pos-
sible interactions with different vaccinations or micro-
nutrients are virtually never reported when a new
intervention is examined, with dire effects as shown
with the high titre measles vaccine.
3
Thirdly, the trial suggests that interventions that are
usuallyconsideredbeneficial mightalsohave negative
consequences under certain circumstances. We and
others have advocated BCG at birth as having benefi-
cial non-specific effects.
41 In the present study BCG
revaccination also had negative effects. In a study
from Bangladesh, children who were vaccinated with
BCG after 9 months of age tended to have increased
mortalityandBCGingeneralwasassociatedwithtwo-
foldincreasedmortalitybetween9monthsand5years
of age, the reported hazard ratio being 2.12 (1.28 to
3.51).
47 As the Bangladeshi children are likely to have
received vitamin A supplementation after 6 months of
age,thisstudymightrepresentasimilarnegativeinter-
action between BCG and vitamin A.
Fourthly, the conduct of the trial was not ideal and
would have benefited from stopping rules and a data
monitoring and safety board because we might have
been unduly cautious in stopping the trial too early.
Randomised trials are doubly difficult to conduct in
low income countries, however, where unexpected
events and unplanned outside interventions during
the trial commonly occur. Thus a flexible and
interactive monitoring system to support investigators
in the field is necessary but expensive.
Fifthly, international public health assumes that our
common interventions have the expected beneficial
effectsirrespectiveofotherconditions.Thereare,how-
ever, an increasing number of studies documenting
that this is not the case. Most interventions have not
been tested for their impact on child survival even
though reduction in child mortality is the justification
for the intervention. But even when they have been
found to reduce mortality in randomised clinical trials
the conditions under which they were tested might
change and negate the beneficial effect. Given the
lack of studies and general surveillance of mortality
and interventions in low income countries we might
simply not know that the beneficial impact has disap-
peared.
Unanswered questions and future research
In the analysis and presentation of this trial, the unex-
pected cluster of deaths took precedence. The main
research question was whether BCG revaccination
after the age at which children receive booster DTP
vaccination had a beneficial effect on child survival.
Fewer children than expected had received booster
DTP and many therefore received it after BCG revac-
cination. BCG revaccination had a stronger than
expected beneficial effect among the children who
had received BCG after a DTP booster vaccination,
but the effect was opposite among those who had not
received a DTP booster vaccination, and there was
therefore no overall beneficial effect. In countries
where booster DTP vaccination is still used, it might
be worth testing whether BCG revaccination given to
children who have received the booster dose of DTP
reduces child mortality as suggested by our results.
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